Edgewise Therapeutics, Inc.
NASDAQ:EWTXBiotechnology
+$1.11 today
- Market cap
- $4.45B
- Beta
- 0.30
- P/E (TTM)
- -21.9
- EPS (TTM)
- -$1.64
Volume 0.87M
Average 1.32M
EWTX EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Edgewise Therapeutics, Inc.NASDAQ: EWTX
EPS (Diluted) · Q3 FY2026 · quarter ended Sep 2026
EPS (Diluted) turns positive
Q3 FY2026 EPS (Diluted) was $9.65, compared with -$0.39 a year earlier. Trailing-twelve-month EPS (Diluted) was $8.19.
Context
- EPS (Diluted) grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 5 analysts of -$1.99 (-21.9%) for the fiscal year ending Dec 2026, a slowdown from the -12.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $9.65+1920.8% QoQ
- Last fiscal yearDec 2025
- -$1.63-12.4% YoY
- LTMSep 2026
- $8.19+618.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +2574.4% | +1.0% | -2573.4 pp |
| 1 year | -12.4% | -21.9% | -9.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (1.63) USD
- Year-over-year change
- -12.4%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.63) | -12.4% |
| FY2024 | 2024-12-31 | (1.45) | +7.6% |
| FY2023 | 2023-12-31 | (1.57) | -24.6% |
| FY2022 | 2022-12-31 | (1.26) | -46.5% |
| FY2021 | 2021-12-31 | (0.86) | — |
EPS (Diluted) vs competitors
How EWTX compares with its peers on the latest reported figures
- EWTX's LTM Sep 2026 EPS (Diluted) of $8.19 is the highest of the 10 companies compared; the peer median is -$2.1.
- Its year-over-year change of +618.4% is the highest of 10, against a peer median of -40.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | $8.19 | +618.4% | — | |
| LTM Jun 2026 | -$0.58 | -108.3% | — | |
| LTM Mar 2026 | -$0.96 | +64.4% | — | |
| LTM Mar 2026 | -$1.95 | +30.1% | — | |
| LTM Mar 2026 | -$2.1 | +32.9% | — | |
| LTM Mar 2026 | -$2.1 | -40.9% | — | |
| LTM Mar 2026 | -$2.32 | -63.4% | — | |
| LTM Mar 2026 | -$2.83 | -458.2% | — | |
| LTM Jun 2026 | -$3.33 | +13.7% | — | |
| LTM Mar 2026 | -$4 | -596.1% | — | |
| Peer median (excluding EWTX) | -$2.1 | -40.9% | — | |
Competitors are the stored peer set for EWTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.27M |
| Gross Profit | 0 | 0 | 0 | 0 | (2.27M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 32.19M | 54.03M | 90.91M | 126.97M | 151.39M |
| Selling, General & Admin | 11.03M | 17.63M | 23.45M | 31.87M | 40.02M |
| Operating Expenses | 43.22M | 71.66M | 114.36M | 158.83M | 189.14M |
| Depreciation & Amortization | 272K | 538K | 1.73M | 2.29M | 2.27M |
| EBITDA | (42.54M) | (63.08M) | (98.43M) | (131.52M) | (165.53M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (43.22M) | (71.66M) | (114.36M) | (158.83M) | (191.41M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 402K | 2.66M | 14.19M | 25.02M | 23.61M |
| Interest Expense | 0 | 4.02M | 0 | 0 | 0 |
| Other Income / Expenses | 402K | 4.02M | 14.19M | 25.02M | 23.61M |
| Income Before Tax | (42.81M) | (67.64M) | (100.16M) | (133.81M) | (167.8M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (42.81M) | (67.64M) | (100.16M) | (133.81M) | (167.8M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.86) | (1.26) | (1.57) | (1.45) | (1.63) |
| EPS (Diluted) | (0.86) | (1.26) | (1.57) | (1.45) | (1.63) |
| Weighted Avg Shares | 49.5M | 53.59M | 63.72M | 92.41M | 102.93M |
| Weighted Avg Shares (Diluted) | 49.5M | 53.59M | 63.72M | 92.41M | 102.93M |
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
Intrinsic Alpha fair value
Locked
Current Price
$41.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.